Results 301 to 310 of about 178,943 (330)
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Apolipoprotein A-I mimetic peptides
Current Opinion in Lipidology, 2010To review published data related to the potential applicability of apolipoprotein A-I mimetic peptides.Despite a wealth of information on HDL-C levels and risk for cardiovascular disease (CVD), little evidence is present to suggest that raising HDL-C levels per se will result in CVD risk reduction.
G K, Hovingh +2 more
+5 more sources
Journal of Pediatric Gastroenterology and Nutrition, 1990
The apolipoprotein (apo) A‐I:B ratio and the apo B concentration were determined by radial immunodiffusion in dried blood spot samples from 1,767 10‐and 11‐year‐old children. Children with either apo A‐I:B ratios below the first percentile or apo B levels above the 99th were recalled and plasma lipid and apolipoprotein profiles were determined for both
Tomas Sveger +4 more
openaire +1 more source
The apolipoprotein (apo) A‐I:B ratio and the apo B concentration were determined by radial immunodiffusion in dried blood spot samples from 1,767 10‐and 11‐year‐old children. Children with either apo A‐I:B ratios below the first percentile or apo B levels above the 99th were recalled and plasma lipid and apolipoprotein profiles were determined for both
Tomas Sveger +4 more
openaire +1 more source
Apolipoprotein A-I in Liver Disease
Scandinavian Journal of Gastroenterology, 1987Apolipoprotein A-I and high-density lipoprotein concentrations in the plasma of patients with liver disease have been found to be either normal or lower than normal. In this study the apolipoprotein A-I concentration was measured in the plasma of 19 patients with cholestatic liver disease and 21 patients with noncholestatic liver disease.
C H, Florén, J, Franzén, J J, Albers
openaire +2 more sources
Apolipoprotein B, apolipoprotein A-I, insulin resistance and the metabolic syndrome
Current Opinion in Lipidology, 2007The goal of identifying subjects with metabolic syndrome is to detect those at higher risk of developing cardiovascular disease. Evidence continues to accumulate as to the superiority of apolipoprotein B and apolipoprotein A-I over the conventional lipoprotein lipids as markers of vascular risk.
Allan D, Sniderman, May, Faraj
openaire +2 more sources
Biochemistry, 2002
Apolipoprotein A-I(Milano) (apoA-I(Milano)) and apoA-I(Paris) are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-I(WT)). In this study,
John K, Bielicki, Michael N, Oda
openaire +2 more sources
Apolipoprotein A-I(Milano) (apoA-I(Milano)) and apoA-I(Paris) are rare cysteine variants of apoA-I that produce a HDL deficiency in the absence of cardiovascular disease in humans. This paradox provides the basis for the hypothesis that the cysteine variants possess a beneficial activity not associated with wild-type apoA-I (apoA-I(WT)). In this study,
John K, Bielicki, Michael N, Oda
openaire +2 more sources
Apolipoprotein A-I-containing lipoproteins and atherosclerosis
Current Opinion in Lipidology, 1995Apolipoprotein A-I-containing lipoproteins represent a heterogeneous group of lipoparticles. Recent studies suggest that a specific subpopulation within the lipoprotein (AI) subclass may be more effective than other lipoproteins in promoting cholesterol efflux from cells and in the different steps of reverse cholesterol transport. This review describes
A, Leroy +2 more
openaire +2 more sources
Human Gene Therapy, 2000
Elevation of HDL cholesterol, after adenoviral apolipoprotein A-I (apo A-I) gene transfer, may delay or revert ischemic cardiovascular disease, provided transgene expression is persistent. Previously, we observed transient human apo A-I expression after adenoviral gene transfer with a cytomegalovirus (CMV)-driven construct containing the human apo A-I ...
B, De Geest +4 more
openaire +2 more sources
Elevation of HDL cholesterol, after adenoviral apolipoprotein A-I (apo A-I) gene transfer, may delay or revert ischemic cardiovascular disease, provided transgene expression is persistent. Previously, we observed transient human apo A-I expression after adenoviral gene transfer with a cytomegalovirus (CMV)-driven construct containing the human apo A-I ...
B, De Geest +4 more
openaire +2 more sources
Bioscience, Biotechnology, and Biochemistry, 2005
A truncated apolipoprotein (apo) A-I with a molecular weight (M(r)) of 26 kDa was first isolated from the plasma high density lipoproteins of an atypical Japanese eel (Anguilla japonica). Interestingly, this eel contained a very small amount of intact apoA-I (M(r)28 kDa) in the plasma, although serine protease inhibitors were present throughout the ...
Seiichi, Ando +3 more
openaire +2 more sources
A truncated apolipoprotein (apo) A-I with a molecular weight (M(r)) of 26 kDa was first isolated from the plasma high density lipoproteins of an atypical Japanese eel (Anguilla japonica). Interestingly, this eel contained a very small amount of intact apoA-I (M(r)28 kDa) in the plasma, although serine protease inhibitors were present throughout the ...
Seiichi, Ando +3 more
openaire +2 more sources